Emerging Companies

The keys to successful industrial biotech business relationships mirror those for successful personal relationships, industry leaders explained today.  During the final Lunch Plenary Session of BIO’s 2011 World Congress in Toronto, moderator James Stoppert, CEO of BioAdvisors, along with panelists Patrick Gruber, CEO of Gevo, Ron Commander, Head of Butyl Rubber Business Unit at Lanxess, Christophe Schilling, CEO of Genomatica, and Hisao Urata, General Manager of Corporate Planning at Mitsubishi Chemical discussed “Strategic Partnerships for More Robust Value Chains” and identified some key components to that end.

Today, major players in the clean energy investment community provided key perspective and insight to help inform industrial biotech companies and their future success.

Bonnie Fendrock talks about her career in the life-sciences industry, including the commercialization of their microliver platform.

Bonnie Fendrock, co-founder, president, and CEO of Hepregen Corporation, talks about her career in the life-sciences industry and the work of Hepregen — including the commercialization of their microliver platform.

Soelkner discusses the benefits of working with a contract manufacturing organization and how to identify, select and work with CMOs.

VABIO's Mark Herzog discusses biotech in Virginia and the upcoming BIO International Convention in Washington, DC.

Mark Herzog, executive director of the Virginia Biotechnology Association recently discussed the success and challenges facing the burgeoning bioscience industry in his state.

Three biotech luminaries who have succeeded against all odds share their experiences building a biotech company from the ground up in Brazil, China and India.

Current rules resulting from a 2003 Office of Hearings and Appeals decision have inhibited and interfered with the growth and survival of small private biotechnology companies and the development of promising technologies and products

The Agriculture Department has announced additional money for loan guarantees to support construction of new advanced biofuel biorefineries.

Ahrens discusses the 2011 BIO International Convention session “Wait! Our Model Isn’t Dead! We Just Need to Evolve.”

The Maryland initiative’s 10-year plan helps build biotech access to funding

BIOtechNOW talks to GEN's John Sterling regarding the upcoming BIO International Convention.

April 29 2014
Chairperson Mikulski, Ranking Member Shelby, Members of the Committee, thank you for the opportunity to provide you with written testimony on the extremely important topic of driving innovation through federal investments.
November 6 2013
On behalf of the BIO and its 1,100 members, I am writing in strong support of your Start-up Jobs and Innovation Act. I want to thank you for introducing this important legislation, which will spur investment in small biotech companies and other innovative businesses.
July 10 2013
A healthy public market is key to the success of the biotech industry, as growing innovators often turn to an IPO to fund late-stage clinical trials.
July 26 2012
Jeffrey S. Hatfield, President and Chief Executive Officer of Vitae Pharmaceuticals, testified on behalf of BIO about the 10th anniversary of the Sarbanes-Oxley Act.
March 16 2012
On behalf of BIO and its more than 1,100 members, Jim Greenwood submitted a letter to Senate Majority Leader Harry Reid and Minority Leader Mitch McConnell in strong support of H.R. 3606, the Jumpstart Our Business Startups (JOBS) Act.
September 17 2014
Legislation aimed at enhancing capital access and creating jobs
September 4 2014
Washington, D.C. (September 4, 2014) – The Biotechnology Industry Organization (BIO) is pleased to announce the winners of the 2014 BIO Investor Forum Buzz of BIO contest, which recognizes highly innovative companies in the biotech sector. Taking place October 7-8, 2014 at the Palace Hotel in San Francisco, California, the 13th Annual BIO Investor Forum will focus on investment opportunities for early stage and established private companies as well as emerging public companies.
August 6 2014
Survey responses will help inform Prescription Drug User Fee Act VI negotiations
May 9 2014
Bill would strengthen, make permanent critical R&D tax credit
April 9 2014
The House Subcommittee on Capital Markets and Government Sponsored Enterprises held a hearing titled “Legislative Proposals to Enhance Capital Formation for Small and Emerging Growth Companies.” Brian Hahn, Chief Financial Officer of GlycoMimetics, Inc. presented testimony at the hearing on enhancements to the capital markets that can increase access to investors and decrease unnecessary regulatory burdens for emerging biotech companies trading on the public market.